A
2.34
-0.12 (-4.88%)
| Previous Close | 2.46 |
| Open | 2.43 |
| Volume | 279,198 |
| Avg. Volume (3M) | 570,154 |
| Market Cap | 169,012,544 |
| Price / Book | 2.63 |
| 52 Weeks Range | |
| Earnings Date | 12 May 2026 |
| Diluted EPS (TTM) | -1.94 |
| Total Debt/Equity (MRQ) | 19.15% |
| Current Ratio (MRQ) | 8.02 |
| Operating Cash Flow (TTM) | -102.48 M |
| Levered Free Cash Flow (TTM) | -63.62 M |
| Return on Assets (TTM) | -31.31% |
| Return on Equity (TTM) | -55.68% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | Acumen Pharmaceuticals, Inc. | Bearish | Bearish |
AIStockmoo Score
-0.5
| Analyst Consensus | -2.0 |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | -0.5 |
| Average | -0.50 |
|
Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believes to be a key underlying cause of Alzheimer's disease. The company's drug candidate, ACU193, is a subclass monoclonal antibody that selectively targets amyloid-beta oligomers. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 11.46% |
| % Held by Institutions | 72.24% |
No data within this time range.
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |